Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. 1998

N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
Department of Internal Medicine III, Erasmus University Rotterdam, The Netherlands.

Corticotropinomas are characterized by a relative resistance to the negative feedback action of cortisol on ACTH secretion. In this respect there is a similarity with the clinical syndrome of cortisol resistance. As cortisol resistance can be caused by genetic abnormalities in the glucocorticoid receptor (GR) gene, we investigated whether the insensitivity of corticotropinomas to cortisol is also caused by de novo mutations in the GR gene. We screened for the GR gene in leukocyte and tumor DNA from 22 patients with Cushing's disease for mutations using PCR/single strand conformation polymorphism analysis. In a previous study, we identified 5 polymorphisms in the GR gene in a normal population. These polymorphisms were used as markers for the possible occurrence of loss of heterozygosity (LOH) at the GR gene locus. Except for 1 silent point mutation, we did not identify novel mutations in the GR gene in leukocytes or corticotropinomas from these patients. Of the 22 patients, 18 were heterozygous for at least 1 of the polymorphisms. In 6 of these patients, LOH had occurred in the tumor DNA. Of 21 patients examined for LOH on chromosome 11q13, only 1, with a corticotroph carcinoma, showed allelic deletion. As controls we studied 28 pituitary tumors of other subtypes (11 clinically nonfunctioning, 8 prolactinomas, and 9 GH-producing adenomas) and found evidence for LOH in only 1 prolactinoma. In six patients LOH was found at the GR gene locus (chromosome 5) in DNA derived from adenoma cells. Our observations indicate for the first time that LOH at the GR gene locus is a relatively frequent phenomenon in pituitary adenomas of patients with Cushing's disease. This might explain the relative resistance of the adenoma cells to the inhibitory feedback action of cortisol on ACTH secretion. The specificity of the GR LOH to corticotropinomas supports this concept. Somatic mutations of the GR are not a frequent cause of relative cortisol resistance in these cells.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011965 Receptors, Glucocorticoid Cytoplasmic proteins that specifically bind glucocorticoids and mediate their cellular effects. The glucocorticoid receptor-glucocorticoid complex acts in the nucleus to induce transcription of DNA. Glucocorticoids were named for their actions on blood glucose concentration, but they have equally important effects on protein and fat metabolism. Cortisol is the most important example. Corticoid Type II Receptor,Glucocorticoid Receptors,Glucocorticoids Receptor,Corticoid II Receptor,Corticoid Type II Receptors,Glucocorticoid Receptor,Receptors, Corticoid II,Receptors, Corticoid Type II,Receptors, Glucocorticoids,Corticoid II Receptors,Glucocorticoids Receptors,Receptor, Corticoid II,Receptor, Glucocorticoid,Receptor, Glucocorticoids
D002880 Chromosomes, Human, Pair 11 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 11
D002895 Chromosomes, Human, Pair 5 One of the two pairs of human chromosomes in the group B class (CHROMOSOMES, HUMAN, 4-5). Chromosome 5
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas

Related Publications

N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
April 1994, The Journal of clinical endocrinology and metabolism,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
November 2004, Journal of endocrinological investigation,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
August 1999, Journal of neuro-oncology,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
November 2001, Journal of endocrinological investigation,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
October 1991, Cancer research,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
March 2017, Endocrine,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
July 1994, Cancer,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
June 1992, Cancer research,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
July 1995, Blood,
N A Huizenga, and P de Lange, and J W Koper, and R N Clayton, and W E Farrell, and A J van der Lely, and A O Brinkmann, and F H de Jong, and S W Lamberts
May 2010, Breast cancer research and treatment,
Copied contents to your clipboard!